Mutares SE & Co. KGaA (MUX)
XETRA Stock Exchange · Germany · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 28.50 |
|---|---|
| 52-week range | 23.25 – 34.43 |
| Return, 1 month / 3 months | +15.2% / +5.9% |
| Return, 1 year / 3 years | +10.9% / +23.5% |
| Trend | Uptrend |
| RSI (14) | 72 |
| Volatility (1 year) | 33.6% |
| Worst drawdown (1 year) | -32.1% |
| Average daily value traded | 0.91M EUR |
| Dividend yield | 7.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Mutares is a German private equity company based in Munich that acquires companies in special situations, often taking over businesses that larger groups want to divest or that need operational improvement. It works with mid-sized industrial and service companies across Europe, helping to restructure their operations and develop them over time. The firm also manages a portfolio of holdings in sectors such as automotive, engineering and logistics, and it invests alongside its own management teams.
Mutares SE & Co. KGaA trades under the code MUX on the XETRA Stock Exchange in Germany, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Mutares SE & Co. KGaA (MUX) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 28.50 on 23 October 2026.
Its price-based Market X-Ray is 62 out of 100 (a fair price profile), ranking 218 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 10.9% and over the last three months it rose 5.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 58 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 8.0% | ||
| From 52-week high | -16.8% | ||
| Momentum | 68 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 5.9% | ||
| 6-month return | 26.5% | ||
| 12-month return, skipping the last month | -3.7% | ||
| Stability (higher is calmer) | 52 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 33.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -32.1% | ||
| Liquidity | 70 · Strong | Trades actively. | |
| Average daily value traded | 0.91M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 71 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 7.0% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
- Income: Dividend is high and has been paid regularly.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +17.0% |
|---|---|
| 1 month | +15.2% |
| 3 months | +5.9% |
| 6 months | +26.5% |
| 1 year | +10.9% |
| 3 years | +23.5% |
| 5 years | +80.4% |
Signals
| 50-day / 200-day average | 25.53 / 26.39 |
|---|---|
| Golden / death cross (60 days) | Death, 29 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.87 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 6 Jul 2026 | EUR 2.0000 |
| 3 Jul 2025 | EUR 1.9620 |
| 5 Jun 2024 | EUR 2.2073 |
| 11 Jul 2023 | EUR 1.7168 |
| 18 May 2022 | EUR 1.4715 |
| 21 May 2021 | EUR 1.4715 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.